Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solasia Pharma KKFRA:9SO 70 Debt-to-Equity is 0.05 as of Jun. 2026, which is 67% above its 10-year median of 0.03. GuruFocus rates FRA:9SO with a GF Score™ of 70/100 and a GF Value™ of €0.15 (Fairly Valued). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, Solasia Pharma KK ranks better than 82.61% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Solasia Pharma KK's Debt-to-Equity or its related term are showing as below:
FRA:9SO'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 5.33
Current: 0.05
During the past 13 years, the highest Debt-to-Equity Ratio of Solasia Pharma KK was 5.33. The lowest was 0.01. And the median was 0.03.
FRA:9SO's Debt-to-Equity is ranked better than 82.61% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs FRA:9SO: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Solasia Pharma KK Debt-to-Equity Related Terms
Solasia Pharma KK Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Solasia Pharma KK's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solasia Pharma KK (FRA:9SO) has a Debt-to-Equity of 0.05 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Solasia Pharma KK and its competitors. This is 67% above median its historical median of 0.03. Over the past decade, Solasia Pharma KK's Debt-to-Equity has ranged from 0.01 to 5.33. According to the industry distribution chart, Solasia Pharma KK ranks #141 out of 811 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Solasia Pharma KK's Debt-to-Equity too high?
Solasia Pharma KK's current Debt-to-Equity of 0.05 is 67% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 5.33. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Solasia Pharma KK's value of 0.05 is 81.5% below this industry median. Based on the distribution chart, Solasia Pharma KK ranks #141 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #141 out of 811 companies for Debt-to-Equity. This places Solasia Pharma KK in the top 17% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Solasia Pharma KK's value of 0.05 is 81.5% below this benchmark. Historically, Solasia Pharma KK's own Debt-to-Equity has ranged from 0.01 to 5.33 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.27, Solasia Pharma KK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasia Pharma KK's current Debt-to-Equity of 0.05 is 81.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Solasia Pharma KK and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current Debt-to-Equity is 0.05, which is 67% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (FRA:9SO) is currently considered Fairly Valued. The stock's GF Value™ is €0.15, compared to a current price of €0.14 — trading 8.7% below its estimated fair value. The current Debt-to-Equity is 0.05, which is 67% above median its 10-year median of 0.03 and 81.5% below the Drug Manufacturers industry median of 0.27. Solasia Pharma KK's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Solasia Pharma KK (FRA:9SO), the current Debt-to-Equity is 0.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (FRA:9SO) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be undervalued.
The current stock price of €0.14 is trading 8.7% below its estimated GF Value™ of €0.15.
GuruFocus considers Solasia Pharma KK to be Fairly Valued.
Key valuation signals for FRA:9SO:
Debt-to-Equity: 0.05 (67% above median its 10-year median of 0.03)
GF Value™: €0.15 vs. price of €0.14 (8.7% below fair value)
Industry Position: 81.5% below the Drug Manufacturers median (#141 of 811)
No single metric tells the full story. See the FRA:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9SO has been successfully added to your 
